A형 간염 백신 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of hepatitis A vaccines Market

The global hepatitis A vaccines market is witnessing strong growth due to rising disease prevalence, expanding immunization programs, and increasing government initiatives aimed at preventing hepatitis A infections. According to the report, the market size reached USD 1.24 billion in 2024, is expected to grow to USD 1.26 billion in 2025, and is projected to rise significantly to USD 2.57 billion by 2032, registering a robust CAGR of 10.7% during the forecast period. With a 50% market share in 2024, North America remained the dominant region, reflecting advanced healthcare systems and strong adoption of immunization practices.

Hepatitis A is a viral liver infection transmitted primarily through contaminated food and water or via close personal contact. Symptoms range from fever, nausea, and abdominal discomfort to jaundice and acute liver failure. The infection is particularly prevalent in low- and middle-income regions due to insufficient sanitation, poor hygiene, and restricted access to clean water. As vaccination is the most effective preventive measure, demand for hepatitis A vaccines continues to grow worldwide. Leading companies such as GSK plc, Sanofi, Merck & Co., Inc., and SINOVAC offer globally approved vaccines, contributing to increasing immunization coverage.

Market Drivers

Growing Prevalence of Hepatitis A

Rising hepatitis A cases globally are driving vaccine uptake. Poor sanitation, contaminated water sources, and limited hygiene practices continue to be major risk factors. In Uzbekistan, for example, 9,507 hepatitis A infections among children were reported in the first two months of 2024, highlighting the urgent need for vaccination programs in high-risk regions.

Increased Government Immunization Initiatives

Governments worldwide are expanding national vaccination programs to prevent outbreaks and minimize healthcare expenditures. In the EU/EEA, 4,548 cases were reported in 2022, prompting authorities to reinforce vaccination strategies.

Market Restraints

High Vaccine Costs and Limited Access

Production of hepatitis A vaccines requires cold-chain logistics and stringent regulatory compliance, elevating overall costs. This restricts access in low-income countries. In Mexico, the cost per dose is USD 935.7, and full immunization requires two doses-making the vaccine unaffordable for many. This affordability gap continues to hinder global eradication efforts.

Market Opportunities

Indigenous Vaccine Development in Emerging Markets

Countries such as India and China are investing in domestic vaccine development to reduce reliance on imports. In January 2024, Indian Immunologicals Ltd launched Havisure, India's first indigenously developed hepatitis A vaccine, significantly improving accessibility and affordability. Such regional innovations are expected to create substantial market opportunities through 2032.

Market Challenges

Cold-Chain Inefficiencies

Hepatitis A vaccines must be stored between 2°C and 8°C. Many lower-income regions lack adequate cold-chain infrastructure, resulting in vaccine wastage and reduced immunization coverage. These limitations remain a key barrier to market expansion.

Market Trends

Rising Demand for Traveler Immunization

With global travel increasing, the demand for hepatitis A vaccination among travelers has grown significantly. Travel clinics and pharmacies in high-income countries report strong vaccine uptake as travelers visit hepatitis A-endemic nations. South Korea, for example, strongly recommends at least one dose before travel to at-risk regions.

Segmentation Overview

By Type

The inactivated vaccine segment dominated the market in 2024 due to global approvals and wide availability. In 2023, SINOVAC's inactivated vaccine Healive gained regulatory approval in Kyrgyzstan. Live attenuated vaccines, though effective, remain regionally concentrated in India and China.

By Age Group

The pediatric segment led the market due to established vaccination protocols. The U.S. CDC recommends routine vaccination for all children aged 12-23 months.

By Form

Solution-based vaccines such as Vaqta (Merck) and Havrix (GSK) hold the majority share due to ease of administration. Lyophilized powders remain important for extended shelf life and storage benefits.

By Distribution Channel

Government suppliers dominated in 2024, driven by large-scale procurement programs. In 2025, GAVI allocated USD 250 million to enhance vaccine access in low-income countries.

Regional Outlook

North America - USD 0.62 Billion in 2024

North America led the global market, supported by high vaccination rates and rising disease incidence. The U.S. alone recorded 44,660 outbreak cases between 2016 and 2020, fueling vaccine demand.

Asia Pacific

Second-largest market with the highest projected CAGR. India, for instance, reported over 6,000 cases in the first half of 2024, prompting rapid vaccine adoption.

Europe

Strong government immunization programs and recent vaccine initiatives contribute to steady growth.

Latin America & Middle East/Africa

Despite lower market shares, rising awareness and targeted health campaigns support gradual adoption.

Conclusion

With the market valued at USD 1.24 billion in 2024, expected to reach USD 1.26 billion in 2025, and projected to attain USD 2.57 billion by 2032, the global hepatitis A vaccines market is positioned for substantial long-term expansion. Increasing disease burden, rising vaccination initiatives, and new indigenous vaccine developments will collectively drive growth throughout the forecast period.

Segmentation By Type

• Inactivated
• Live Attenuated
• Others

By Age Group

• Pediatric
• Adults

By Form

• Solution
• Lyophilized Powder

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Region

• North America (By Type, Age Group, Dose, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Hepatitis A - by Key Countries/Regions, 2024
• 4.2. Pipeline Analysis, by Key Players
• 4.3. Technological Advancements in Market
• 4.4. New Product Launches, by Key Players
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Inactivated
  • 5.1.2. Live Attenuated
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Age Group
  • 5.2.1. Pediatric
  • 5.2.2. Adolts
• 5.3. Market Analysis, Insights and Forecast - By Form
  • 5.3.1. Solution
  • 5.3.2. Lyophilized Powder
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital & Retail Pharmacies
  • 5.4.2. Government Suppliers
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Inactivated
  • 6.1.2. Live Attenuated
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Age Group
  • 6.2.1. Pediatric
  • 6.2.2. Adolts
• 6.3. Market Analysis, Insights and Forecast - By Form
  • 6.3.1. Solution
  • 6.3.2. Lyophilized Powder
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital & Retail Pharmacies
  • 6.4.2. Government Suppliers
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. S.
  • 6.5.2. Canada

7. Europe Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Inactivated
  • 7.1.2. Live Attenuated
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Age Group
  • 7.2.1. Pediatric
  • 7.2.2. Adolts
• 7.3. Market Analysis, Insights and Forecast - By Form
  • 7.3.1. Solution
  • 7.3.2. Lyophilized Powder
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital & Retail Pharmacies
  • 7.4.2. Government Suppliers
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Inactivated
  • 8.1.2. Live Attenuated
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Age Group
  • 8.2.1. Pediatric
  • 8.2.2. Adolts
• 8.3. Market Analysis, Insights and Forecast - By Form
  • 8.3.1. Solution
  • 8.3.2. Lyophilized Powder
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital & Retail Pharmacies
  • 8.4.2. Government Suppliers
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Inactivated
  • 9.1.2. Live Attenuated
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Age Group
  • 9.2.1. Pediatric
  • 9.2.2. Adolts
• 9.3. Market Analysis, Insights and Forecast - By Form
  • 9.3.1. Solution
  • 9.3.2. Lyophilized Powder
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital & Retail Pharmacies
  • 9.4.2. Government Suppliers
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Inactivated
  • 10.1.2. Live Attenuated
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Age Group
  • 10.2.1. Pediatric
  • 10.2.2. Adolts
• 10.3. Market Analysis, Insights and Forecast - By Form
  • 10.3.1. Solution
  • 10.3.2. Lyophilized Powder
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital & Retail Pharmacies
  • 10.4.2. Government Suppliers
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. GSK plc
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Sanofi
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck & Co., Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Wockhardt
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Indian Immunologicals Ltd (IIL)
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. SINOVAC
    • 11.2.6.1. Overview
      • 11.2.6.1.1. Products & services
      • 11.2.6.1.2. SWOT Analysis
      • 11.2.6.1.3. Recent Developments
      • 11.2.6.1.4. Strategies
      • 11.2.6.1.5. Financials (Based on Availability)
  • 11.2.7. Vaxines Trading, Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Boryung Biopharma Co.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)